DexCom, Inc. (NASDAQ:DXCM) EVP Sells $274,241.90 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

DexCom Trading Down 1.9 %

Shares of NASDAQ:DXCM opened at $133.86 on Thursday. The business’s 50-day moving average is $129.20 and its 200 day moving average is $116.28. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The firm has a market capitalization of $51.61 billion, a P/E ratio of 102.18, a P/E/G ratio of 2.31 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the company posted $0.34 EPS. The firm’s quarterly revenue was up 26.9% compared to the same quarter last year. On average, research analysts predict that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on DXCM. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Raymond James lifted their target price on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Finally, UBS Group boosted their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $141.40.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its stake in DexCom by 31.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock valued at $138,643,000 after purchasing an additional 65,516 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in DexCom by 3,596.7% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock valued at $567,000 after purchasing an additional 1,079 shares during the last quarter. West Family Investments Inc. purchased a new stake in DexCom during the 1st quarter valued at about $209,000. Ergoteles LLC grew its stake in DexCom by 60.6% during the 1st quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock valued at $860,000 after purchasing an additional 634 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in DexCom by 26.4% during the 1st quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock valued at $15,100,000 after purchasing an additional 6,160 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.